Cargando…
In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug
PCC0104005 is a novel drug candidate for treating schizophrenia that displays high affinity for serotonin, dopamine, and noradrenaline receptors, including partial agonism at dopamine D(2), D(3), D(4), serotonin 5-HT(1A), and 5-HT(2A) receptors and antagonism at 5-HT(2B), 5-HT(6), and 5-HT(7) recept...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931996/ https://www.ncbi.nlm.nih.gov/pubmed/29720711 http://dx.doi.org/10.1038/s41598-018-25036-0 |